PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Study Identifier:
D6780C00004
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
Date
Nov 2024 - Apr 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 6 - 17 Years
Requirements Information
Sex
Female & Male
Age
6 - 17 Years
Study Details
Medical Condition
- Unmapped
Study Drug
Date
Nov 2024 - Apr 2027
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 6 - 17 Years years
Requirements Information
Protocol Summary
The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
Trial Locations
Location
Status
Location
Research Site
Washington, District of Columbia, United States, 20010
Status
Recruiting
Location
Research Site
Norfolk, Virginia, United States, 23507
Status
Recruiting
Location
Research Site
Joinville, Brazil, 89202-451
Status
Not yet recruiting
Location
Research Site
Salvador, Brazil, 41253-190
Status
Not yet recruiting
Location
Research Site
Sao Jose Do Rio Preto, Brazil, 15090-000
Status
Not yet recruiting
Location
Research Site
Sao Paulo, Brazil, 05403-000
Status
Not yet recruiting